Treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy.

The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole.

With this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.

Treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy.

The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole.

Although most of these data have been studied in populations with long-term follow-up, such as breast cancer, cardiac toxicity and the reduced survival it entails are also found in diseases such as esophageal cancer.

With this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.

Inclusion Criteria:

• Age ≥ 18 years
• Histologically or cytologically proven esophageal cancer
• Localized or locally advanced esophageal cancer treated with radiochemotherapy or exclusive radiotherapy
• Tumor dose ≥ 50 Gy
• Non-opposition of living patients formulated
• Patient affiliated to a social security scheme

Exclusion Criteria:

• Age < 18 years
• Patient treated with upfront surgery
• Tumor dose < 50 Gy
• Other concomitant neoplasia
• Metastatic patient
• Refusal to participate
• Patient under legal protection (guardianship, curatorship, etc...)

Non-operated adult patients with localized or locally advanced esophageal cancer treated with radiochemotherapy or radiotherapy alone for curative purposes.

All collected data that underlie results in a publication

Data will be available beginning three years and ending fifteen years following the final study report completion

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement